Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data
Journal of Opioid Management · 2024
DOI: 10.5055/jom.0878 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Opioid Management, 2024. Verfasst von Jody L Green und 2 weiteren Autor:innen. Beteiligte Einrichtung: Uprise Health/Inflexxion, Irvine, California. ORCID: https://orcid.org/0000-0003-1776-6400. Hauptthemen laut MEDLINE: Oxycodone, Opioid-Related Disorders, Analgesics, Opioid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objective
The United States (US) opioid epidemic is a continued burden on the healthcare system and on the lives of individuals affected by the consequences of opioid abuse/misuse. The objective of this study was to use real-world data from intentional abuse/misuse exposures managed by US poison centers to compare clinical outcomes and quantify healthcare costs among three study cohorts: exposures that involved Xtampza ER®, other oxycodone extended-release (ER), and oxycodone immediate-release (IR). Study design: A real-world, observational study. Main outcome measures: Descriptive statistics were used to describe patient and exposure characteristics. Drug utilization-adjusted rates of intentional abuse/misuse and clinical outcomes were used to determine relative risk. Healthcare cost estimates were calculated by extrapolating average charge per opioid-related disorder emergency department (ED) visit and per inpatient stay based upon case disposition rates, adjusted for population and drug utilization.
Results
Compared to Xtampza ER, exposures that involved other oxycodone ER were 7.4 times more likely to be intentional abuse/misuse, 25.9 times more likely to result in major effect or death, 9.7 times more likely to require a visit to the ED, and 14.3 times more likely to result in hospital admission. Similar results were found for oxycodone IR when compared to Xtampza ER.
Conclusions
This study is the first of its kind to synthesize clinical outcomes with opioid-related healthcare costs, suggesting that even when Xtampza ER is abused/misused, the rates of major effect/death, ED visits, and hospital admissions were significantly lower than those for other oxycodone-containing medications, resulting in relatively low downstream opioid-related healthcare costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Uprise Health/Inflexxion, Irvine, California. ORCID: https://orcid.org/0000-0003-1776-6400.
- Uprise Health/Inflexxion, Irvine, California. ORCID: https://orcid.org/0000-0002-2942-4267.
- Uprise Health/Inflexxion, Irvine, California. ORCID: https://orcid.org/0000-0002-1794-7116.
Zitieren
APA
Green, J. L., Dailey-Govoni, T., & Vosburg, S. K. (2024). Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data. Journal of Opioid Management. https://doi.org/10.5055/jom.0878
Vancouver
Green JL, Dailey-Govoni T, Vosburg SK. Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data. Journal of Opioid Management. 2024. doi:10.5055/jom.0878
BibTeX
@article{Green2024,
author = {Green, Jody L and Dailey-Govoni, Taryn and Vosburg, Suzanne K},
title = {Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data},
journal = {Journal of Opioid Management},
year = {2024},
doi = {10.5055/jom.0878}
}
EUVIMED